Skip to Main Content

Paper Details

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach.
Oncotarget
14
2021
Author NameAffiliation
Baldo OlivaUniversitat Pompeu Fabra
  • 1 - 1

Datasets

Release 1.2